Arca
Skip to content

Lower respiratory tract infection

Drug research and approvals for lower respiratory tract infection: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 16, 2026, 33 studies of lower respiratory tract infection are recruiting on ClinicalTrials.gov, and Health Canada has authorized 8 drug trials for it since 2013.

  • Recruiting worldwide: 33
  • Trials authorized in Canada: 8
  • FDA orphan approvals: 0
  • EU medicines: 0

Recruiting Now

Newest start dates first, of 33 recruiting on ClinicalTrials.gov ↗

Trials Authorized in Canada

Newest first; search them all in Canada trials
Feb 26, 2025A multi center, adaptive, randomized, controlled trial platform to evaluate safety and efficacy of strategies and treatments for hospitalized patients with…OrenciaUniversity Of MinnesotaPending
Aug 10, 2023An interventional, phase 1b, randomized, double-blind, sponsor-open, placebo-controlled, multi-center, dose-finding study to evaluate safety, tolerability and…Sisunatovir (PF-07923568)PfizerClosed
Sep 29, 2022A phase 3, observer-blind, randomized, placebo-controlled study to evaluate the noninferiority of the immune response and safety of the rsvpref3 oa…RSVPREF3GSKOngoing
Apr 27, 2022Assessment of qbkpn site-specific immunomodulator (ssi) efficacy in improving innate immune function and reducing all-cause respiratory tract infection…Qbkpn site specific immunomodulator (ssi)Qu Biologics IncOngoing
Jul 23, 2021A randomized, double-blind, placebo-controlled phase 3 efficacy study of an ad26.rsv.pref-based vaccine in the prevention of lower respiratory tract disease…VAC18193 (JNJ-64400141/JNJ-64213175 (AD26/PROTEIN pref rsv vaccine))Johnson & JohnsonClosed
Aug 14, 2019A multicenter, randomized, double blind, placebo-controlled, phase 3 study to determine if rtb101 prevents clinically symptomatic respiratory illness in the…Dactolisib (RTB101, BEZ235)Restorbio IncOngoing
Jul 26, 2017An open label safety study of inhaled gaseous nitric oxide (gno) for adults with non-tuberculosis mycobacteria infectionNitric oxideDr Jeremy RoadPending
Jul 10, 2015A phase 2b, parallel-group, double blind, placebo-controlled, multicenter study of syn-004 compared to placebo for the prevention of clostridium difficile…SYN-004 (recombinant modified class a b-lactamase)Synthetic Biologics, IncOngoing

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.